Opinion|Videos|November 20, 2025
Subgroup Analysis From the Phase 3 EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor
Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.
Advertisement
Episodes in this series
An additional subgroup analysis examined outcomes based on prior endocrine therapy (ET) duration and CDK4/6 inhibitor exposure. Patients with a longer prior duration of ET plus CDK4/6 inhibitor showed a clinically meaningful improvement in PFS when treated with elacestrant compared to standard of care. This suggests that tumors retaining partial endocrine sensitivity particularly with ESR1 mutations—derive the greatest benefit from selective estrogen receptor degrader-based therapy.
Advertisement
Related to this article
Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
4
Closing the outpatient monitoring gap in cancer
5